WO2005107798A1 - NEISSERIA MENINGITIDIS IgtB LOS AS ADJUVANT - Google Patents
NEISSERIA MENINGITIDIS IgtB LOS AS ADJUVANT Download PDFInfo
- Publication number
- WO2005107798A1 WO2005107798A1 PCT/NL2005/000358 NL2005000358W WO2005107798A1 WO 2005107798 A1 WO2005107798 A1 WO 2005107798A1 NL 2005000358 W NL2005000358 W NL 2005000358W WO 2005107798 A1 WO2005107798 A1 WO 2005107798A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipid
- moiety
- los
- neisserial
- neisserial los
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE602005020608T DE602005020608D1 (en) | 2004-05-11 | 2005-05-11 | NEISSERIA MENINGITIDIS IgtB LESS THAN ADJUVANS |
US11/596,319 US20080138359A1 (en) | 2004-05-11 | 2005-05-11 | Neisseria meningitidis lgtb Los as Adjuvant |
AT05745670T ATE464066T1 (en) | 2004-05-11 | 2005-05-11 | NEISSERIA MENINGITIDIS IGTB LOS AS ADJUVANT |
MXPA06013093A MXPA06013093A (en) | 2004-05-11 | 2005-05-11 | Neisseria meningitidis. |
KR1020067026018A KR101270838B1 (en) | 2004-05-11 | 2005-05-11 | NEISSERIA MENINGITIDIS IgtB LOS AS ADJUVANT |
DK05745670.9T DK1748791T3 (en) | 2004-05-11 | 2005-05-11 | Neisseria Meningitidis IgtB LOS as an adjuvant |
CN2005800181701A CN1997392B (en) | 2004-05-11 | 2005-05-11 | Neisseria meningitidis igtB LOS as adjuvant |
AU2005239963A AU2005239963B2 (en) | 2004-05-11 | 2005-05-11 | Neisseria meningitidis IgtB LOS as adjuvant |
PL05745670T PL1748791T3 (en) | 2004-05-11 | 2005-05-11 | NEISSERIA MENINGITIDIS IgtB LOS AS ADJUVANT |
CA2566409A CA2566409C (en) | 2004-05-11 | 2005-05-11 | Neisseria meningitidis igtb lipo-oligo-saccharides as adjuvant |
BRPI0511026A BRPI0511026C1 (en) | 2004-05-11 | 2005-05-11 | use of a neisserial, and, composition |
NZ551250A NZ551250A (en) | 2004-05-11 | 2005-05-11 | Neisseria meningitidis 1gtB LOS as adjuvant |
JP2007513087A JP5174457B2 (en) | 2004-05-11 | 2005-05-11 | Neisseria meningitidis lgtBLOS as an adjuvant |
EP05745670A EP1748791B1 (en) | 2004-05-11 | 2005-05-11 | NEISSERIA MENINGITIDIS IgtB LOS AS ADJUVANT |
SI200531025T SI1748791T1 (en) | 2004-05-11 | 2005-05-11 | NEISSERIA MENINGITIDIS IgtB LOS AS ADJUVANT |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04076401 | 2004-05-11 | ||
EP04076401.1 | 2004-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005107798A1 true WO2005107798A1 (en) | 2005-11-17 |
Family
ID=34928212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2005/000358 WO2005107798A1 (en) | 2004-05-11 | 2005-05-11 | NEISSERIA MENINGITIDIS IgtB LOS AS ADJUVANT |
Country Status (18)
Country | Link |
---|---|
US (1) | US20080138359A1 (en) |
EP (1) | EP1748791B1 (en) |
JP (1) | JP5174457B2 (en) |
KR (1) | KR101270838B1 (en) |
CN (1) | CN1997392B (en) |
AT (1) | ATE464066T1 (en) |
AU (1) | AU2005239963B2 (en) |
BR (1) | BRPI0511026C1 (en) |
CA (1) | CA2566409C (en) |
DE (1) | DE602005020608D1 (en) |
DK (1) | DK1748791T3 (en) |
ES (1) | ES2344114T3 (en) |
MX (1) | MXPA06013093A (en) |
NZ (1) | NZ551250A (en) |
PL (1) | PL1748791T3 (en) |
PT (1) | PT1748791E (en) |
SI (1) | SI1748791T1 (en) |
WO (1) | WO2005107798A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007071710A2 (en) | 2005-12-22 | 2007-06-28 | Glaxosmithkline Biologicals Sa | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
WO2007116028A2 (en) | 2006-04-07 | 2007-10-18 | Glaxosmithkline Biologicals S.A. | Conjugate vaccines |
WO2010130899A1 (en) * | 2009-05-14 | 2010-11-18 | Sanofi Pasteur | Meningococcal vaccine based on lipooligosaccharide (los) and neisseria meningitidis protein |
WO2011015591A1 (en) | 2009-08-05 | 2011-02-10 | Glaxosmithkline Biologicals S.A. | Immunogenic composition comprising antigenic s. aureus proteins |
WO2011015590A1 (en) | 2009-08-05 | 2011-02-10 | Glaxosmithkline Biologicals S.A. | Immunogenic composition comprising variants of staphylococcal clumping factor a |
WO2011110241A1 (en) | 2010-03-09 | 2011-09-15 | Glaxosmithkline Biologicals S.A. | Immunogenic composition comprising s. pneumoniae polysaccharides conjugated to carrier proteins |
WO2011110570A1 (en) | 2010-03-09 | 2011-09-15 | Glaxosmithkline Biologicals S.A. | Treatment of streptococcal infections |
WO2011117408A1 (en) | 2010-03-26 | 2011-09-29 | Glaxosmithkline Biologicals S.A. | Hiv vaccine |
EP2476434A1 (en) | 2006-03-30 | 2012-07-18 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
WO2013006055A1 (en) | 2011-07-07 | 2013-01-10 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws | A process for detergent-free production of outer membrane vesicles |
EP2687228A2 (en) | 2007-06-26 | 2014-01-22 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
WO2014195280A1 (en) | 2013-06-05 | 2014-12-11 | Glaxosmithkline Biologicals S.A. | Immunogenic composition for use in therapy |
WO2016091904A1 (en) | 2014-12-10 | 2016-06-16 | Glaxosmithkline Biologicals Sa | Method of treatment |
EP3263695A1 (en) | 2016-06-29 | 2018-01-03 | GlaxoSmithKline Biologicals SA | Immunogenic compositions |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9904581D0 (en) * | 1999-12-15 | 1999-12-15 | A & Science Invest Ab | A novel helicobacter pylori-binding substance and its use |
US8642046B2 (en) * | 2007-10-09 | 2014-02-04 | Tufts University | Cholera vaccines |
JP5723768B2 (en) * | 2008-05-30 | 2015-05-27 | ザ ユナイテッド ステイツ オブ アメリカ, アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー, オン ビハーフ オブ ウォルター リード アーミー インスティチュート オブ リサーチ | Meningococcal multivalent native outer membrane vesicle vaccine, its preparation method and use thereof |
WO2010130898A2 (en) | 2009-05-14 | 2010-11-18 | Sanofi Pasteur | Menigococcus vaccine containing lipooligosaccharide (los) from modified strains of l6 immunotype neisseria meningitidis |
EA201390452A1 (en) | 2010-09-27 | 2013-11-29 | Глаксосмитклайн Байолоджикалс С.А. | VACCINE |
KR20120068647A (en) * | 2010-12-18 | 2012-06-27 | 아이진 주식회사 | Vaccines capable of inducing enhanced immune responses |
KR102002034B1 (en) | 2015-07-09 | 2019-07-22 | 에스에프씨주식회사 | organic light-emitting diode with High efficiency and long lifetime |
EP3533463A4 (en) * | 2016-10-31 | 2020-06-17 | Eyegene Inc. | Immune response regulatory substance and vaccine composition containing same |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL9101359A (en) | 1991-08-07 | 1993-03-01 | Nederlanden Staat | New saccharide-peptide conjugate, method for the production thereof, and a vaccine which contains such a saccharide-peptide conjugate. |
WO2000026384A1 (en) | 1998-11-03 | 2000-05-11 | De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Lps with reduced toxicity from genetically modified gram negative bacteria |
WO2004014417A2 (en) | 2002-08-02 | 2004-02-19 | Glaxosmithkline Biologicals Sa | Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0103170D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
CA2458854A1 (en) * | 2001-08-31 | 2003-03-06 | Chiron Srl | Helicobacter pylori vaccination |
US20090123499A1 (en) * | 2006-06-12 | 2009-05-14 | Nathalie Devos | Vaccine |
-
2005
- 2005-05-11 AT AT05745670T patent/ATE464066T1/en active
- 2005-05-11 US US11/596,319 patent/US20080138359A1/en not_active Abandoned
- 2005-05-11 JP JP2007513087A patent/JP5174457B2/en not_active Expired - Fee Related
- 2005-05-11 MX MXPA06013093A patent/MXPA06013093A/en active IP Right Grant
- 2005-05-11 SI SI200531025T patent/SI1748791T1/en unknown
- 2005-05-11 CN CN2005800181701A patent/CN1997392B/en not_active Expired - Fee Related
- 2005-05-11 EP EP05745670A patent/EP1748791B1/en active Active
- 2005-05-11 AU AU2005239963A patent/AU2005239963B2/en not_active Ceased
- 2005-05-11 DE DE602005020608T patent/DE602005020608D1/en active Active
- 2005-05-11 DK DK05745670.9T patent/DK1748791T3/en active
- 2005-05-11 ES ES05745670T patent/ES2344114T3/en active Active
- 2005-05-11 PT PT05745670T patent/PT1748791E/en unknown
- 2005-05-11 CA CA2566409A patent/CA2566409C/en not_active Expired - Fee Related
- 2005-05-11 PL PL05745670T patent/PL1748791T3/en unknown
- 2005-05-11 NZ NZ551250A patent/NZ551250A/en not_active IP Right Cessation
- 2005-05-11 WO PCT/NL2005/000358 patent/WO2005107798A1/en active Application Filing
- 2005-05-11 BR BRPI0511026A patent/BRPI0511026C1/en not_active IP Right Cessation
- 2005-05-11 KR KR1020067026018A patent/KR101270838B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL9101359A (en) | 1991-08-07 | 1993-03-01 | Nederlanden Staat | New saccharide-peptide conjugate, method for the production thereof, and a vaccine which contains such a saccharide-peptide conjugate. |
WO2000026384A1 (en) | 1998-11-03 | 2000-05-11 | De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Lps with reduced toxicity from genetically modified gram negative bacteria |
WO2004014417A2 (en) | 2002-08-02 | 2004-02-19 | Glaxosmithkline Biologicals Sa | Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis |
Non-Patent Citations (4)
Title |
---|
LEY VAN DER P ET AL: "MODIFICATION OF LIPID A BIOSYNTHESIS IN NEISSERIA MENINGITIDIS IPXLMUTANTS: INFLUENCE ON LIPOPOLYSACCHARIDE STRUCTURE, TOXICITY AND ADJUVANT ACTIVITY", INFECTION AND IMMUNITY, AMERICAN SOCIETY OF MICROBIOLOGY, WASHINGTON, DC, US, vol. 69, no. 10, October 2001 (2001-10-01), pages 5981 - 5990, XP001055221, ISSN: 0019-9567 * |
LEY; LEY ET AL., INFECT.IMMUN., vol. 69, 2001, pages 5981 - 5990 |
STEEGHS ET AL., J. ENDOTOXIN RES., vol. 10, 2004, pages 113 - 119 |
STEEGHS LIANA ET AL: "Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development.", JOURNAL OF ENDOTOXIN RESEARCH, vol. 10, no. 2, April 2004 (2004-04-01), pages 113 - 119, XP009038407, ISSN: 0968-0519 * |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10646564B2 (en) | 2005-12-22 | 2020-05-12 | Glaxosmithkline Biologicals S.A. | Vaccine |
WO2007071711A2 (en) | 2005-12-22 | 2007-06-28 | Glaxosmithkline Biologicals Sa | Vaccine |
US10279033B2 (en) | 2005-12-22 | 2019-05-07 | Glaxosmithkline Biologicals Sa | Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates |
EP3020411A1 (en) | 2005-12-22 | 2016-05-18 | GlaxoSmithKline Biologicals s.a. | Vaccine |
EP2402025A2 (en) | 2005-12-22 | 2012-01-04 | GlaxoSmithKline Biologicals S.A. | Vaccine |
EP2382986A2 (en) | 2005-12-22 | 2011-11-02 | GlaxoSmithKline Biologicals s.a. | Vaccine against streptococcus pneumoniae |
WO2007071710A2 (en) | 2005-12-22 | 2007-06-28 | Glaxosmithkline Biologicals Sa | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
US11400147B2 (en) | 2005-12-22 | 2022-08-02 | Glaxosmithkline Biologicals Sa | Pneumococcal capsular saccharide conjugate vaccine |
EP2476434A1 (en) | 2006-03-30 | 2012-07-18 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
EP2476433A1 (en) | 2006-03-30 | 2012-07-18 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
EP3141261A1 (en) | 2006-03-30 | 2017-03-15 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
EP2392346A1 (en) | 2006-04-07 | 2011-12-07 | GlaxoSmithKline Biologicals SA | Streptococcus pneumoniae vaccine |
WO2007116028A2 (en) | 2006-04-07 | 2007-10-18 | Glaxosmithkline Biologicals S.A. | Conjugate vaccines |
EP2687228A2 (en) | 2007-06-26 | 2014-01-22 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
WO2010130899A1 (en) * | 2009-05-14 | 2010-11-18 | Sanofi Pasteur | Meningococcal vaccine based on lipooligosaccharide (los) and neisseria meningitidis protein |
WO2011015590A1 (en) | 2009-08-05 | 2011-02-10 | Glaxosmithkline Biologicals S.A. | Immunogenic composition comprising variants of staphylococcal clumping factor a |
WO2011015591A1 (en) | 2009-08-05 | 2011-02-10 | Glaxosmithkline Biologicals S.A. | Immunogenic composition comprising antigenic s. aureus proteins |
WO2011110241A1 (en) | 2010-03-09 | 2011-09-15 | Glaxosmithkline Biologicals S.A. | Immunogenic composition comprising s. pneumoniae polysaccharides conjugated to carrier proteins |
WO2011110570A1 (en) | 2010-03-09 | 2011-09-15 | Glaxosmithkline Biologicals S.A. | Treatment of streptococcal infections |
WO2011117408A1 (en) | 2010-03-26 | 2011-09-29 | Glaxosmithkline Biologicals S.A. | Hiv vaccine |
WO2013006055A1 (en) | 2011-07-07 | 2013-01-10 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws | A process for detergent-free production of outer membrane vesicles |
WO2014195280A1 (en) | 2013-06-05 | 2014-12-11 | Glaxosmithkline Biologicals S.A. | Immunogenic composition for use in therapy |
WO2016091904A1 (en) | 2014-12-10 | 2016-06-16 | Glaxosmithkline Biologicals Sa | Method of treatment |
EP3263695A1 (en) | 2016-06-29 | 2018-01-03 | GlaxoSmithKline Biologicals SA | Immunogenic compositions |
WO2018002270A1 (en) | 2016-06-29 | 2018-01-04 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions |
US11679149B2 (en) | 2016-06-29 | 2023-06-20 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
Also Published As
Publication number | Publication date |
---|---|
EP1748791B1 (en) | 2010-04-14 |
DE602005020608D1 (en) | 2010-05-27 |
MXPA06013093A (en) | 2007-08-08 |
DK1748791T3 (en) | 2010-06-28 |
US20080138359A1 (en) | 2008-06-12 |
JP2007537248A (en) | 2007-12-20 |
KR20070029742A (en) | 2007-03-14 |
CN1997392A (en) | 2007-07-11 |
PT1748791E (en) | 2010-07-15 |
NZ551250A (en) | 2010-03-26 |
ES2344114T3 (en) | 2010-08-18 |
CN1997392B (en) | 2011-06-01 |
BRPI0511026A (en) | 2007-11-27 |
PL1748791T3 (en) | 2010-08-31 |
EP1748791A1 (en) | 2007-02-07 |
ATE464066T1 (en) | 2010-04-15 |
KR101270838B1 (en) | 2013-07-04 |
BRPI0511026C1 (en) | 2021-05-25 |
CA2566409C (en) | 2012-12-04 |
AU2005239963B2 (en) | 2011-01-06 |
JP5174457B2 (en) | 2013-04-03 |
SI1748791T1 (en) | 2010-07-30 |
CA2566409A1 (en) | 2005-11-17 |
BRPI0511026B1 (en) | 2019-01-08 |
AU2005239963A1 (en) | 2005-11-17 |
BRPI0511026B8 (en) | 2020-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2566409C (en) | Neisseria meningitidis igtb lipo-oligo-saccharides as adjuvant | |
US20080317769A1 (en) | Vaccine Composition Comprising Alpha-Galactosylceramide as an Adjuvant For Intranasal Administration | |
CN102245204A (en) | Alpha-galactosyl ceramide analogs and their use as immunotherapies, adjuvants, and intiviral, antibacterial, and anticancer agents | |
JP2008535868A (en) | Immunomodulatory composition and uses therefor | |
RU2348428C2 (en) | Functionally reconstructed adjuvant-containing virus membranes | |
JP2007508328A (en) | Immunomodulatory compositions and methods of use thereof | |
EP2029165A1 (en) | B cell-based vaccine loaded with the ligand of natural killer t cell and antigen | |
Fransen et al. | Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B | |
JP5860871B2 (en) | Novel immune adjuvant compounds and uses thereof | |
KR101566847B1 (en) | Use of glycosylceramides for enhancing the immune response to antigens | |
ES2322212T3 (en) | COMPOSITION OF ANTIGEN AND CELL LINE THAT CARRIES THE HANDY RECEIVER. | |
Zughaier et al. | TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A | |
US8003093B2 (en) | B cell-based vaccine loaded with the ligand of natural killer T cell and antigen | |
AU2008360937B2 (en) | Methods of enhancing adjuvanticity of vaccine compositions | |
US20090136546A1 (en) | Immunomodulating compositions and uses therefor | |
AU2011211337B2 (en) | Immunomodulating compositions and uses therefor | |
AU2006235222A1 (en) | Immunomodulating compositions and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005745670 Country of ref document: EP Ref document number: 2566409 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/013093 Country of ref document: MX Ref document number: 551250 Country of ref document: NZ Ref document number: 2005239963 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007513087 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580018170.1 Country of ref document: CN Ref document number: 3610/KOLNP/2006 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2005239963 Country of ref document: AU Date of ref document: 20050511 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005239963 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067026018 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005745670 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067026018 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11596319 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0511026 Country of ref document: BR |